Galanin receptor ligands. 2005

Xiaoying Lu, and Linda Lundström, and Ulo Langel, and Tamas Bartfai
Department of Neuropharmacology, The Harold L. Dorris Neurological Research Center, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA.

The three galanin receptor subtypes (GalR1-3) belong to the G protein-coupled receptor superfamily. The widespread distribution of galanin and its receptors in the CNS and PNS and the numerous physiological and pharmacological effects of galanin (for review, cf. Vrontakis, 2002) render the three galanin receptors attractive drug targets. The industrial efforts, however, have not yet resulted in a wealth of receptor subtype specific agonists or antagonists with high affinity and selectivity. The present paper summarizes the properties of the galanin ligands used at the end of 2004 in the ca. 2000 publications and complements their pharmacological characterization with new data.

UI MeSH Term Description Entries
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D009479 Neuropeptides Peptides released by NEURONS as intercellular messengers. Many neuropeptides are also hormones released by non-neuronal cells. Neuropeptide
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D044088 Receptors, Galanin A family of G-protein-coupled receptors that are specific for GALANIN and galanin peptides. They are generally considered to be coupled to the GI, INHIBITORY G-PROTEIN to meditate the neurological effects of galanin. Several subtypes of galanin receptors occur with differing specificities for the full length galanin, galanin peptide fragments, and galanin-like peptide. Galanin Receptor,Galanin Receptors,Receptor, Galanin

Related Publications

Xiaoying Lu, and Linda Lundström, and Ulo Langel, and Tamas Bartfai
January 2015, SpringerPlus,
Xiaoying Lu, and Linda Lundström, and Ulo Langel, and Tamas Bartfai
January 1998, The journal of peptide research : official journal of the American Peptide Society,
Xiaoying Lu, and Linda Lundström, and Ulo Langel, and Tamas Bartfai
December 1998, Annals of the New York Academy of Sciences,
Xiaoying Lu, and Linda Lundström, and Ulo Langel, and Tamas Bartfai
April 1989, European journal of biochemistry,
Xiaoying Lu, and Linda Lundström, and Ulo Langel, and Tamas Bartfai
May 2011, Neurochemistry international,
Xiaoying Lu, and Linda Lundström, and Ulo Langel, and Tamas Bartfai
January 2012, Frontiers in endocrinology,
Xiaoying Lu, and Linda Lundström, and Ulo Langel, and Tamas Bartfai
September 1991, International journal of peptide and protein research,
Xiaoying Lu, and Linda Lundström, and Ulo Langel, and Tamas Bartfai
October 2013, Journal of neurochemistry,
Xiaoying Lu, and Linda Lundström, and Ulo Langel, and Tamas Bartfai
December 1998, Annals of the New York Academy of Sciences,
Xiaoying Lu, and Linda Lundström, and Ulo Langel, and Tamas Bartfai
March 2000, Trends in pharmacological sciences,
Copied contents to your clipboard!